China Approves Sovleplenib in Two Autoimmune Blood Diseases

China approved oral Syk inhibitor sovleplenib for previously treated chronic primary immune thrombocytopenia and corticosteroid-insufficient warm autoimmune hemolytic anemia on November 19. Two distinct blood-disease labels create a meaningful domestic regulatory validation; foreign approval…




